Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 23 entries
Sorted by: Best Match Show Resources per page
Genetic Characterization of Ten-Eleven-Translocation Methylcytosine Dioxygenase Alterations in Human Glioma.

Journal of Cancer

Kraus TF, Greiner A, Steinmaurer M, Dietinger V, Guibourt V, Kretzschmar HA.
PMID: 26284134
J Cancer. 2015 Jul 15;6(9):832-42. doi: 10.7150/jca.12010. eCollection 2015.

The molecular mechanisms leading to brain tumors still remain unclear. Nevertheless, there is increasing evidence that epigenetic effects play crucial roles in tumor development and progression. Thereby, 5-hydroxymethylcytosine (5hmC) represents a further base modification of cytosine besides 5-methylcytosine (5mC)....

Cite
Kraus TF, Greiner A, Steinmaurer M, et al. Genetic Characterization of Ten-Eleven-Translocation Methylcytosine Dioxygenase Alterations in Human Glioma. J Cancer. 2015;6(9):832-42doi: 10.7150/jca.12010.
Kraus, T. F., Greiner, A., Steinmaurer, M., Dietinger, V., Guibourt, V., & Kretzschmar, H. A. (2015). Genetic Characterization of Ten-Eleven-Translocation Methylcytosine Dioxygenase Alterations in Human Glioma. Journal of Cancer, 6(9), 832-42. https://doi.org/10.7150/jca.12010
Kraus, Theo F J, et al. "Genetic Characterization of Ten-Eleven-Translocation Methylcytosine Dioxygenase Alterations in Human Glioma." Journal of Cancer vol. 6,9 (2015): 832-42. doi: https://doi.org/10.7150/jca.12010
Kraus TF, Greiner A, Steinmaurer M, Dietinger V, Guibourt V, Kretzschmar HA. Genetic Characterization of Ten-Eleven-Translocation Methylcytosine Dioxygenase Alterations in Human Glioma. J Cancer. 2015 Jul 15;6(9):832-42. doi: 10.7150/jca.12010. eCollection 2015. PMID: 26284134; PMCID: PMC4532980.
Copy Download .nbib Format: NLM
Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program.

Translational oncology

Cassier PA, Peyramaure C, Attignon V, Eberst L, Pacaud C, Boyault S, Desseigne F, Sarabi M, Guibert P, Rochefort P, Marques N, Rivoire M, Dupré A, Peyrat P, Terret C, Ray-Coquard I, Coutzac C, Pérol D, Blay JY, Trédan O, de la Fouchardière C.
PMID: 34794033
Transl Oncol. 2022 Jan;15(1):101266. doi: 10.1016/j.tranon.2021.101266. Epub 2021 Nov 15.

BACKGROUND: Chemotherapy, anti-HER2 and PD-1 antibodies are standard treatments but only a minority of patients derive long-term benefit from these agents.METHODS: In this report we describe the mutational landscape and outcome of patients with gastroesophageal cancers enroled in the...

Cite
Cassier PA, Peyramaure C, Attignon V, et al. Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program. Transl Oncol. 2021;15(1):101266doi: 10.1016/j.tranon.2021.101266.
Cassier, P. A., Peyramaure, C., Attignon, V., Eberst, L., Pacaud, C., Boyault, S., Desseigne, F., Sarabi, M., Guibert, P., Rochefort, P., Marques, N., Rivoire, M., Dupré, A., Peyrat, P., Terret, C., Ray-Coquard, I., Coutzac, C., Pérol, D., Blay, J. Y., Trédan, O., & de la Fouchardière, C. (2022). Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program. Translational oncology, 15(1), 101266. https://doi.org/10.1016/j.tranon.2021.101266
Cassier, Philippe A, et al. "Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program." Translational oncology vol. 15,1 (2022): 101266. doi: https://doi.org/10.1016/j.tranon.2021.101266
Cassier PA, Peyramaure C, Attignon V, Eberst L, Pacaud C, Boyault S, Desseigne F, Sarabi M, Guibert P, Rochefort P, Marques N, Rivoire M, Dupré A, Peyrat P, Terret C, Ray-Coquard I, Coutzac C, Pérol D, Blay JY, Trédan O, de la Fouchardière C. Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program. Transl Oncol. 2022 Jan;15(1):101266. doi: 10.1016/j.tranon.2021.101266. Epub 2021 Nov 15. PMID: 34794033; PMCID: PMC8605190.
Copy Download .nbib Format: NLM
Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report.

Frontiers in oncology

Varnier R, Garrivier T, Hafliger E, Favre A, Coutzac C, Spire C, Rochefort P, Sarabi M, Desseigne F, Guibert P, Cattey-Javouhey A, Funk-Debleds P, Mastier C, Buisson A, Pérol D, Trédan O, Blay JY, Phelip JM, de la Fouchardiere C.
PMID: 34631593
Front Oncol. 2021 Sep 24;11:756365. doi: 10.3389/fonc.2021.756365. eCollection 2021.

Immune checkpoint inhibitors (ICI) have been developed in gastric adenocarcinomas and approved in first-line metastatic setting (in combination with chemotherapy) as well as in pretreated patients. Microsatellite instability-high (MSI-H) tumors are predicted to derive high benefit from ICI but...

Cite
Varnier R, Garrivier T, Hafliger E, et al. Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report. Front Oncol. 2021;11:756365doi: 10.3389/fonc.2021.756365.
Varnier, R., Garrivier, T., Hafliger, E., Favre, A., Coutzac, C., Spire, C., Rochefort, P., Sarabi, M., Desseigne, F., Guibert, P., Cattey-Javouhey, A., Funk-Debleds, P., Mastier, C., Buisson, A., Pérol, D., Trédan, O., Blay, J. Y., Phelip, J. M., & de la Fouchardiere, C. (2021). Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report. Frontiers in oncology, 11756365. https://doi.org/10.3389/fonc.2021.756365
Varnier, Romain, et al. "Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report." Frontiers in oncology vol. 11 (2021): 756365. doi: https://doi.org/10.3389/fonc.2021.756365
Varnier R, Garrivier T, Hafliger E, Favre A, Coutzac C, Spire C, Rochefort P, Sarabi M, Desseigne F, Guibert P, Cattey-Javouhey A, Funk-Debleds P, Mastier C, Buisson A, Pérol D, Trédan O, Blay JY, Phelip JM, de la Fouchardiere C. Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report. Front Oncol. 2021 Sep 24;11:756365. doi: 10.3389/fonc.2021.756365. eCollection 2021. PMID: 34631593; PMCID: PMC8499695.
Copy Download .nbib Format: NLM
Intensive care units, the Achilles heel of France in the COVID-19 battle.

The Lancet regional health. Europe

Annane D, Federici L, Chagnon JL, Diehl JL, Dreyfuss D, Guiot P, Javouhey E, Joram N, Lesieur O, Rigaud JP, Outin H, Sement A, Sevens C, Thévenin D, Touati S, Terzi N.
PMID: 34173634
Lancet Reg Health Eur. 2021 Mar;2:100046. doi: 10.1016/j.lanepe.2021.100046. Epub 2021 Jan 29.

No abstract available.

Cite
Annane D, Federici L, Chagnon JL, et al. Intensive care units, the Achilles heel of France in the COVID-19 battle. Lancet Reg Health Eur. 2021;2:100046doi: 10.1016/j.lanepe.2021.100046.
Annane, D., Federici, L., Chagnon, J. L., Diehl, J. L., Dreyfuss, D., Guiot, P., Javouhey, E., Joram, N., Lesieur, O., Rigaud, J. P., Outin, H., Sement, A., Sevens, C., Thévenin, D., Touati, S., Terzi, N. (2021). Intensive care units, the Achilles heel of France in the COVID-19 battle. The Lancet regional health. Europe, 2100046. https://doi.org/10.1016/j.lanepe.2021.100046
Annane, Djillali, et al. "Intensive care units, the Achilles heel of France in the COVID-19 battle." The Lancet regional health. Europe vol. 2 (2021): 100046. doi: https://doi.org/10.1016/j.lanepe.2021.100046
Annane D, Federici L, Chagnon JL, Diehl JL, Dreyfuss D, Guiot P, Javouhey E, Joram N, Lesieur O, Rigaud JP, Outin H, Sement A, Sevens C, Thévenin D, Touati S, Terzi N. Intensive care units, the Achilles heel of France in the COVID-19 battle. Lancet Reg Health Eur. 2021 Mar;2:100046. doi: 10.1016/j.lanepe.2021.100046. Epub 2021 Jan 29. PMID: 34173634; PMCID: PMC7844353.
Copy Download .nbib Format: NLM
Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program.

Translational oncology

Cassier PA, Peyramaure C, Attignon V, Eberst L, Pacaud C, Boyault S, Desseigne F, Sarabi M, Guibert P, Rochefort P, Marques N, Rivoire M, Dupré A, Peyrat P, Terret C, Ray-Coquard I, Coutzac C, Pérol D, Blay JY, Trédan O, de la Fouchardière C.
PMID: 34794033
Transl Oncol. 2021 Nov 15;15(1):101266. doi: 10.1016/j.tranon.2021.101266. Epub 2021 Nov 15.

BACKGROUND: Chemotherapy, anti-HER2 and PD-1 antibodies are standard treatments but only a minority of patients derive long-term benefit from these agents.METHODS: In this report we describe the mutational landscape and outcome of patients with gastroesophageal cancers enroled in the...

Cite
Cassier PA, Peyramaure C, Attignon V, et al. Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program. Transl Oncol. 2021;15(1):101266doi: 10.1016/j.tranon.2021.101266.
Cassier, P. A., Peyramaure, C., Attignon, V., Eberst, L., Pacaud, C., Boyault, S., Desseigne, F., Sarabi, M., Guibert, P., Rochefort, P., Marques, N., Rivoire, M., Dupré, A., Peyrat, P., Terret, C., Ray-Coquard, I., Coutzac, C., Pérol, D., Blay, J. Y., Trédan, O., & de la Fouchardière, C. (2021). Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program. Translational oncology, 15(1), 101266. https://doi.org/10.1016/j.tranon.2021.101266
Cassier, Philippe A, et al. "Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program." Translational oncology vol. 15,1 (2021): 101266. doi: https://doi.org/10.1016/j.tranon.2021.101266
Cassier PA, Peyramaure C, Attignon V, Eberst L, Pacaud C, Boyault S, Desseigne F, Sarabi M, Guibert P, Rochefort P, Marques N, Rivoire M, Dupré A, Peyrat P, Terret C, Ray-Coquard I, Coutzac C, Pérol D, Blay JY, Trédan O, de la Fouchardière C. Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program. Transl Oncol. 2021 Nov 15;15(1):101266. doi: 10.1016/j.tranon.2021.101266. Epub 2021 Nov 15. PMID: 34794033; PMCID: PMC8605190.
Copy Download .nbib Format: NLM
20-Hydroxyecdysone activates the protective arm of the RAAS via the MAS receptor.

Journal of molecular endocrinology

Lafont R, Serova M, Didry-Barca B, Raynal S, Guibout L, Dinan L, Veillet S, Latil M, Dioh W, Dilda PJ.
PMID: 34825653
J Mol Endocrinol. 2021 Dec 23;68(2):77-87. doi: 10.1530/JME-21-0033.

20-Hydroxyecdysone (20E) is a steroid hormone that plays a key role in insect development through nuclear ecdysteroid receptors (EcR/RXR complex) and at least one membrane GPCR receptor (DopEcR). It also displays numerous pharmacological effects in mammals, where its mechanism...

Cite
Lafont R, Serova M, Didry-Barca B, et al. 20-Hydroxyecdysone activates the protective arm of the RAAS via the MAS receptor. J Mol Endocrinol. 2021;68(2):77-87doi: 10.1530/JME-21-0033.
Lafont, R., Serova, M., Didry-Barca, B., Raynal, S., Guibout, L., Dinan, L., Veillet, S., Latil, M., Dioh, W., & Dilda, P. J. (2021). 20-Hydroxyecdysone activates the protective arm of the RAAS via the MAS receptor. Journal of molecular endocrinology, 68(2), 77-87. https://doi.org/10.1530/JME-21-0033
Lafont, René, et al. "20-Hydroxyecdysone activates the protective arm of the RAAS via the MAS receptor." Journal of molecular endocrinology vol. 68,2 (2021): 77-87. doi: https://doi.org/10.1530/JME-21-0033
Lafont R, Serova M, Didry-Barca B, Raynal S, Guibout L, Dinan L, Veillet S, Latil M, Dioh W, Dilda PJ. 20-Hydroxyecdysone activates the protective arm of the RAAS via the MAS receptor. J Mol Endocrinol. 2021 Dec 23;68(2):77-87. doi: 10.1530/JME-21-0033. PMID: 34825653.
Copy Download .nbib Format: NLM
Oral Condition and Incident Coronary Heart Disease: A Clustering Analysis.

Journal of dental research

Deraz O, Rangé H, Boutouyrie P, Chatzopoulou E, Asselin A, Guibout C, Van Sloten T, Bougouin W, Andrieu M, Vedié B, Thomas F, Danchin N, Jouven X, Bouchard P, Empana JP.
PMID: 34875909
J Dent Res. 2021 Dec 07;220345211052507. doi: 10.1177/00220345211052507. Epub 2021 Dec 07.

Poor oral health has been linked to coronary heart disease (CHD). Clustering clinical oral conditions routinely recorded in adults may identify their CHD risk profile. Participants from the Paris Prospective Study 3 received, between 2008 and 2012, a baseline...

Cite
Deraz O, Rangé H, Boutouyrie P, et al. Oral Condition and Incident Coronary Heart Disease: A Clustering Analysis. J Dent Res. 2021;220345211052507doi: 10.1177/00220345211052507.
Deraz, O., Rangé, H., Boutouyrie, P., Chatzopoulou, E., Asselin, A., Guibout, C., Van Sloten, T., Bougouin, W., Andrieu, M., Vedié, B., Thomas, F., Danchin, N., Jouven, X., Bouchard, P., & Empana, J. P. (2021). Oral Condition and Incident Coronary Heart Disease: A Clustering Analysis. Journal of dental research, 220345211052507. https://doi.org/10.1177/00220345211052507
Deraz, O, et al. "Oral Condition and Incident Coronary Heart Disease: A Clustering Analysis." Journal of dental research vol. (2021): 220345211052507. doi: https://doi.org/10.1177/00220345211052507
Deraz O, Rangé H, Boutouyrie P, Chatzopoulou E, Asselin A, Guibout C, Van Sloten T, Bougouin W, Andrieu M, Vedié B, Thomas F, Danchin N, Jouven X, Bouchard P, Empana JP. Oral Condition and Incident Coronary Heart Disease: A Clustering Analysis. J Dent Res. 2021 Dec 07;220345211052507. doi: 10.1177/00220345211052507. Epub 2021 Dec 07. PMID: 34875909.
Copy Download .nbib Format: NLM
Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program.

Translational oncology

Cassier PA, Peyramaure C, Attignon V, Eberst L, Pacaud C, Boyault S, Desseigne F, Sarabi M, Guibert P, Rochefort P, Marques N, Rivoire M, Dupré A, Peyrat P, Terret C, Ray-Coquard I, Coutzac C, Pérol D, Blay JY, Trédan O, de la Fouchardière C.
PMID: 34794033
Transl Oncol. 2021 Nov 15;15(1):101266. doi: 10.1016/j.tranon.2021.101266. Epub 2021 Nov 15.

BACKGROUND: Chemotherapy, anti-HER2 and PD-1 antibodies are standard treatments but only a minority of patients derive long-term benefit from these agents.METHODS: In this report we describe the mutational landscape and outcome of patients with gastroesophageal cancers enroled in the...

Cite
Cassier PA, Peyramaure C, Attignon V, et al. Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program. Transl Oncol. 2021;15(1):101266doi: 10.1016/j.tranon.2021.101266.
Cassier, P. A., Peyramaure, C., Attignon, V., Eberst, L., Pacaud, C., Boyault, S., Desseigne, F., Sarabi, M., Guibert, P., Rochefort, P., Marques, N., Rivoire, M., Dupré, A., Peyrat, P., Terret, C., Ray-Coquard, I., Coutzac, C., Pérol, D., Blay, J. Y., Trédan, O., & de la Fouchardière, C. (2021). Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program. Translational oncology, 15(1), 101266. https://doi.org/10.1016/j.tranon.2021.101266
Cassier, Philippe A, et al. "Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program." Translational oncology vol. 15,1 (2021): 101266. doi: https://doi.org/10.1016/j.tranon.2021.101266
Cassier PA, Peyramaure C, Attignon V, Eberst L, Pacaud C, Boyault S, Desseigne F, Sarabi M, Guibert P, Rochefort P, Marques N, Rivoire M, Dupré A, Peyrat P, Terret C, Ray-Coquard I, Coutzac C, Pérol D, Blay JY, Trédan O, de la Fouchardière C. Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program. Transl Oncol. 2021 Nov 15;15(1):101266. doi: 10.1016/j.tranon.2021.101266. Epub 2021 Nov 15. PMID: 34794033; PMCID: PMC8605190.
Copy Download .nbib Format: NLM
Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program.

Translational oncology

Cassier PA, Peyramaure C, Attignon V, Eberst L, Pacaud C, Boyault S, Desseigne F, Sarabi M, Guibert P, Rochefort P, Marques N, Rivoire M, Dupré A, Peyrat P, Terret C, Ray-Coquard I, Coutzac C, Pérol D, Blay JY, Trédan O, de la Fouchardière C.
PMID: 34794033
Transl Oncol. 2021 Nov 15;15(1):101266. doi: 10.1016/j.tranon.2021.101266. Epub 2021 Nov 15.

BACKGROUND: Chemotherapy, anti-HER2 and PD-1 antibodies are standard treatments but only a minority of patients derive long-term benefit from these agents.METHODS: In this report we describe the mutational landscape and outcome of patients with gastroesophageal cancers enroled in the...

Cite
Cassier PA, Peyramaure C, Attignon V, et al. Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program. Transl Oncol. 2021;15(1):101266doi: 10.1016/j.tranon.2021.101266.
Cassier, P. A., Peyramaure, C., Attignon, V., Eberst, L., Pacaud, C., Boyault, S., Desseigne, F., Sarabi, M., Guibert, P., Rochefort, P., Marques, N., Rivoire, M., Dupré, A., Peyrat, P., Terret, C., Ray-Coquard, I., Coutzac, C., Pérol, D., Blay, J. Y., Trédan, O., & de la Fouchardière, C. (2021). Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program. Translational oncology, 15(1), 101266. https://doi.org/10.1016/j.tranon.2021.101266
Cassier, Philippe A, et al. "Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program." Translational oncology vol. 15,1 (2021): 101266. doi: https://doi.org/10.1016/j.tranon.2021.101266
Cassier PA, Peyramaure C, Attignon V, Eberst L, Pacaud C, Boyault S, Desseigne F, Sarabi M, Guibert P, Rochefort P, Marques N, Rivoire M, Dupré A, Peyrat P, Terret C, Ray-Coquard I, Coutzac C, Pérol D, Blay JY, Trédan O, de la Fouchardière C. Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program. Transl Oncol. 2021 Nov 15;15(1):101266. doi: 10.1016/j.tranon.2021.101266. Epub 2021 Nov 15. PMID: 34794033; PMCID: PMC8605190.
Copy Download .nbib Format: NLM
Effect of Platelet-activating Factor on in vitro and in vivo Interleukin-6 Production.

Mediators of inflammation

Pignol B, Maisonnet T, Guinot P, Mencia-Huertac JM, Braquet P.
PMID: 18472953
Mediators Inflamm. 1994;3(4):281-5. doi: 10.1155/S0962935194000384.

The aim of the present study was to investigate the possible effect of platelet-activating factor (PAF), by comparison with interleukin-1beta and polyriboinositic/polyribocytidylic (poly I-C) acid, on IL-6 production by L 929 mouse fibroblasts. At concentrations above 1 muM PAF,...

Cite
Pignol B, Maisonnet T, Guinot P, et al. Effect of Platelet-activating Factor on in vitro and in vivo Interleukin-6 Production. Mediators Inflamm. 1994;3(4):281-5doi: 10.1155/S0962935194000384.
Pignol, B., Maisonnet, T., Guinot, P., Mencia-Huertac, J. M., & Braquet, P. (1994). Effect of Platelet-activating Factor on in vitro and in vivo Interleukin-6 Production. Mediators of inflammation, 3(4), 281-5. https://doi.org/10.1155/S0962935194000384
Pignol, B, et al. "Effect of Platelet-activating Factor on in vitro and in vivo Interleukin-6 Production." Mediators of inflammation vol. 3,4 (1994): 281-5. doi: https://doi.org/10.1155/S0962935194000384
Pignol B, Maisonnet T, Guinot P, Mencia-Huertac JM, Braquet P. Effect of Platelet-activating Factor on in vitro and in vivo Interleukin-6 Production. Mediators Inflamm. 1994;3(4):281-5. doi: 10.1155/S0962935194000384. PMID: 18472953; PMCID: PMC2367046.
Copy Download .nbib Format: NLM
Preparation of explosive nanoparticles in a porous chromium(III) oxide matrix: a first attempt to control the reactivity of explosives.

Nanotechnology

Comet M, Siegert B, Pichot V, Gibot P, Spitzer D.
PMID: 21828750
Nanotechnology. 2008 Jul 16;19(28):285716. doi: 10.1088/0957-4484/19/28/285716. Epub 2008 Jun 03.

This paper reports the first attempt to control the combustion and the detonation properties of a high explosive through its structure. A porous chromium(III) oxide matrix produced by the combustion of ammonium dichromate was infiltrated by hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX). The...

Cite
Comet M, Siegert B, Pichot V, et al. Preparation of explosive nanoparticles in a porous chromium(III) oxide matrix: a first attempt to control the reactivity of explosives. Nanotechnology. 2008;19(28):285716doi: 10.1088/0957-4484/19/28/285716.
Comet, M., Siegert, B., Pichot, V., Gibot, P., & Spitzer, D. (2008). Preparation of explosive nanoparticles in a porous chromium(III) oxide matrix: a first attempt to control the reactivity of explosives. Nanotechnology, 19(28), 285716. https://doi.org/10.1088/0957-4484/19/28/285716
Comet, M, et al. "Preparation of explosive nanoparticles in a porous chromium(III) oxide matrix: a first attempt to control the reactivity of explosives." Nanotechnology vol. 19,28 (2008): 285716. doi: https://doi.org/10.1088/0957-4484/19/28/285716
Comet M, Siegert B, Pichot V, Gibot P, Spitzer D. Preparation of explosive nanoparticles in a porous chromium(III) oxide matrix: a first attempt to control the reactivity of explosives. Nanotechnology. 2008 Jul 16;19(28):285716. doi: 10.1088/0957-4484/19/28/285716. Epub 2008 Jun 03. PMID: 21828750.
Copy Download .nbib Format: NLM
Antisense approach for the treatment of cytomegalovirus infection.

Expert opinion on investigational drugs

Temsamani J, Pari GS, Guinot P.
PMID: 15991890
Expert Opin Investig Drugs. 1997 Sep;6(9):1157-67. doi: 10.1517/13543784.6.9.1157.

Human cytomegalovirus (HCMV) is the most common viral opportunistic infection in patients suffering with acquired immunodeficiency virus (AIDS). HCMV is a systemic infection that may infect several sites in the body, including the retina, gastrointestinal tract, lungs, liver, and...

Cite
Temsamani J, Pari GS, Guinot P. Antisense approach for the treatment of cytomegalovirus infection. Expert Opin Investig Drugs. 1997;6(9):1157-67doi: 10.1517/13543784.6.9.1157.
Temsamani, J., Pari, G. S., & Guinot, P. (1997). Antisense approach for the treatment of cytomegalovirus infection. Expert opinion on investigational drugs, 6(9), 1157-67. https://doi.org/10.1517/13543784.6.9.1157
Temsamani, J, et al. "Antisense approach for the treatment of cytomegalovirus infection." Expert opinion on investigational drugs vol. 6,9 (1997): 1157-67. doi: https://doi.org/10.1517/13543784.6.9.1157
Temsamani J, Pari GS, Guinot P. Antisense approach for the treatment of cytomegalovirus infection. Expert Opin Investig Drugs. 1997 Sep;6(9):1157-67. doi: 10.1517/13543784.6.9.1157. PMID: 15991890.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 23 entries